Introduction
Angiotensin II (Ang II) plays a major role in blood pressure and extracellular fluid volume regulation. These actions involve both acute (vasoconstrictor) and chronic (trophic) effects on blood vessels. In the main, these effects are mediated by AT 1 -receptors. 1 The object of this article is to briefly review the intracellular signalling pathways activated by AT 1 -receptors in vascular smooth muscle, with particular regard to the role of tyrosine kinases.
Ang II has many actions on the cardiovascular system and it should be emphasised that vascular smooth muscle shows heterogeneous responses to Ang II. For example, some blood vessels show limited contraction in response to Ang II 2 and variation is particularly apparent when the trophic effects of Ang II on cultured smooth muscle are considered. Ang II induces little or no DNA synthesis or proliferation in smooth muscle from human coronary artery, 3 human saphenous vein, 4, 5 porcine coronary 6 and aortic cells from normotensive strains of rat 7 but increases protein synthesis or activation of early growth response genes such as c-fos. In contrast, Ang II caused DNA synthesis and/or an increase in cell number when smooth muscle cells from human subcutaneous arteries, 8 aorta of spontaneously hypertensive rats (SHR), 9 porcine ciliary artery, 10 rat mesenteric artery, 11 or rat renal arterioles 12 were studied. In rat aortic smooth muscle cells, the ability of AT 1receptors to induce DNA synthesis may depend on the pattern of secondary growth factors induced, [13] [14] [15] [16] cell-matrix interactions 17 or levels of p27 kip1 . 18 While some differences in response may reflect methodological issues, differences in the pattern of signals evoked by the AT 1 -receptor can also be seen as a mechanism by which a tissue can tailor its response to Ang II. In light of this, differences in signalling patterns are perhaps unsurprising and may be physiologically advantageous.
AT 1 -receptor transduction
The AT 1 -receptor belongs to the superfamily of seven transmembrane domain receptors (R7G) that couples to heterotrimeric G proteins. In man there is only a single subtype of the AT 1 -receptor, but in rodents two subtypes of the AT 1 -receptor exist (AT 1a and AT 1b ). Evidence from gene knockout studies suggests that both AT 1 subtypes can contribute to renal and cardiovascular regulation, 19 but that the AT 1a -receptor may be the more important. 20 As yet, no marked differences have been seen in signals evoked by each subtype. 20 Following binding of Ang II, signal transduction occurs as a result of interaction between the receptor and a heterotrimeric G protein. 21 AT 1 -receptors have been reported to interact with a variety of heterotrimeric G proteins including G q/11 , 22,23 G i , 24 G α12 , 25, 23 and G α13 . 26 Different G protein isoforms are known to couple to different signalling systems, so it is likely that some differences reported in terms of downstream signals could reflect differences in relative quantities of heterotrimeric G protein expressed, or variations in coupling efficiency in a particular tissue or cell type.
Intracellular signals evoked by AT 1 -receptors
Active α and βγ subunits of G proteins initiate a burgeoning cascade of signals within the cell.This field has been intensively studied over the last decade and numerous signals have been described in association with AT 1 -receptor activation (reviewed in 25, 27, 28 ). Of these an increase in intracellular Ca 2+ ([Ca 2+ ] i ) is perhaps one of the earliest described and is generally considered to play a crucial role in mediating Ang II-induced vasoconstriction and to contribute to Ang II-induced growth. The cellular mechanisms responsible for the rise in [Ca 2+ ] i following AT 1 -receptor stimulation have been reviewed elsewhere 28 and are not discussed further here.
Lipid-derived signals
Several studies have stressed the importance of phospholipid-derived messengers in the action of contractile agonists in vascular smooth muscle 29 and Ang II has been reported to increase inositol trisphosphate (IP 3 ) and diacylglycerol (DAG) in vascular smooth muscle through activation of PLC. 30, 31 The identity of the PLC isoform linked to the AT 1 -receptor remains the subject of some dispute. Some studies have failed to detect PLC-β in vascular smooth muscle and it has been suggested that PLC-γ may contribute to the increase in IP 3 and DAG induced by AT 1 -receptors. 32, 33 However, other studies have failed to support this proposal. 34, 23 Unlike PLC, which preferentially acts on phospholipids containing phosphoinositol, phospholipase D (PLD) hydrolyses phosphatidylcholine to produce phosphatidic acid (PA). Since PA and DAG can be interconverted by the action of diacylglycerol kinase and phosphatidic acid phos-phohydrolase respectively; 35 this is another potential source of DAG in the cell. Ang II has been shown to activate PLD in cultured cells 36 and isolated blood vessels. 37 DAG is the physiological activator of PKC and is also a source of arachidonic acid and its metabolites. 38 Currently, numerous isoforms of PKC have been described (reviewed in 39 ) .A number of these may be activated by AT 1 -receptors in vascular smooth muscle, including α, β, δ, ε, µ, ζ and ι/λ. [40] [41] [42] [43] Activation of PCK causes contraction of isolated blood vessels. 29 In some blood vessels this is secondary to an increase in [Ca 2+ ] i , 44 in others Ca 2+ independent mechanisms such as phosphorylation of thin filament proteins, caldesmon and calponin, 29 or inhibition of myosin phosphatase 45 may be more important. The importance of PKC to Ang IIinduced contraction is variable; in some studies, inhibition of PKC attenuates AT 1 -induced contraction, 46 whereas it has little or no effect in others. 43 Data regarding the importance of PKC to Ang II-induced protein synthesis is also conflicting: downregulation of PKC with phorbol ester or inhibition of PKC prevents activation of MAP kinases by Ang II 47, 48 and inhibits 3 H-leucine incorporation in rat aortic smooth muscle cells. 49 DNA synthesis in SHR and WKY aortic cells is also prevented by inhibition of PKC. 50 This may be attributable, at least in part, to the role of PKC in inducing expression of TGF-β and/or other growth factors in response to Ang II. 13 In contrast, another study failed to detect any effect of downregulation of PKC on Ang II-induced protein synthesis in smooth muscle cells cultured from rat aorta. 51 It is possible that differences in the contribution from different PKC isoforms, 48 or redundancy in signalling pathways account for these differences.
Phosphoinositide 3-kinase (PI3K) is a heterodimeric enzyme consisting of a p85 adapter and a p110 catalytic subunit. PI3K catalyses the synthesis of 3-phosphorylated phosphoinositides. The major products of PI3K appear to be involved in regulation of the cytoskeleton, targeting of intracellular membranes and other growth-related processes. 52 Ang II has been reported to activate PI3K, 53 possibly via generation of reactive oxygen species (ROS). 54 Inhibition of PI3K resulted in inhibition of proliferation, DNA synthesis and protein synthesis in smooth muscle cells cultured from porcine coronary artery. 53 However Ang II has also been reported to inhibit insulin-induced activation of PI3K, possibly as a result of impairment of interaction between insulin receptor substrate-1 (IRS-1) and the p85 subunit of PI3K. 55
Tyrosine phosphorylation
One of the most interesting recent developments in the field of AT 1 signalling has been the recognition that receptor activation is associated with increased protein tyrosine phosphorylation.This is an intracellular signal traditionally associated with classical vascular growth factors such as plateletderived growth factor (PDGF) or basic fibroblastderived growth factor (bFGF).
There are now numerous reports showing that Ang II increases levels of tyrosine phosphorylation in cultured vascular smooth muscle cells (reviewed in 25, 27 ). A number of proteins that are tyrosine phosphorylated in response to Ang II have been identified. These include the adaptor protein shc, 56 p42/p44 MAP kinases (ERK1/2), 57 paxillin, 58, 59 the EGF receptor, 60 the PDGF receptor, 56 Axl, 27 c-src, 61 Fyn, 62 Jak-2 62,63 MAPKP-1, 64 the p85 subunit of PI3K, 65 and PLC-γ. 32 In keeping with the recognised importance of this pathway to cell growth, inhibition of tyrosine kinases prevents activation of ERK1/2, protein synthesis or DNA synthesis of vascular smooth muscle cells in response to Ang II. 66, 8, 11 Interestingly, an increase in tyrosine phosphorylation is seen not only in cultured cells, but is also observed in intact blood vessels. 67, 68 Furthermore, inhibitors of tyrosine kinases prevent Ang II-induced vasoconstriction in some vessels. 69 The precise mechanisms involved in this action remain to be determined, but considerable evidence now exists (reviewed in 70 ) linking tyrosine kinases to the regulation of ion channels, Ca 2+ entry and calcium sensitisation in response to a variety of contractile agonists.
Recently, our understanding of the ways by which Ang II increases tyrosine phosphorylation has improved considerably. It is now clear that AT 1receptor stimulation is associated with activation of several different tyrosine kinases by a variety of mechanisms (Figure 1) .
One mechanism involves activation of a Ca 2+dependent tyrosine kinase. The tyrosine kinase involved has recently been identified as CADTK (also known as PYK2, CAK-β, or RAFTK). CADTK is a member of the FAK family and was originally described in neuronal tissue. 71, 72 CADTK is also regulated by PKC and its activation can be prevented by agents that disrupt the cytoskeleton. 73, 72 CADTK is able to phosphorylate a number of downstream targets including focal adhesion kinase (FAK) and the receptor for epidermal growth factor (EGFR). Both these targets are themselves tyrosine kinases with a range of substrates. In rat aortic cells, CADTK-mediated activation of EGFR appears to be required for induction of c-fos, activation of ERK1/2 and protein synthesis in response to Ang II. 74, 75, 60 CADTK may also be involved in p21-activated kinase (PAK) stimulation of c-Jun N-terminal kinase (JNK) by Ang II, as this has been reported to be dependent on Ca 2+ and PKC. 76 AT 1 -receptors are also capable of activating a number of other tyrosine kinases via Ca 2+ -independent mechanisms. The kinases activated include c-src and other members of the src family (such as fyn), the Janus family of tyrosine kinases (JAK), and the PDGF β-receptor (PDGFR).
c-src is a non-receptor cytoplasmic tyrosine kinase present in large amounts in smooth muscle 70 and is activated by Ang II in rat aortic smooth muscle cells. 61 Again, this may involve the production of ROS and much recent data suggests a major role for ROS generated by the NADP/NADH oxidase system in linking AT 1 -receptors to a variety of EDITORIAL REVIEW cellular responses in vascular smooth muscle cells in vivo and in vitro. 77 Activation of c-src has been reported to be required for cytoskeletal reorganisation, focal adhesion formation and cell migration, 78 as well as activation of the ras pathways and proliferation in rat aortic smooth muscle cells. 79 Although the AT 1 -receptor lacks intrinsic tyrosine kinase activity, its C-terminus contains a sequence (YIPP) that can bind and activate the tyrosine kinase, JAK2. 63, 80 This mechanism accounts in part for the ability of Ang II to activate STAT transcription factors in vascular smooth muscle cells, although c-src is probably also involved. 64 In addition, activation of JAK2 appears to be responsible for activation of fyn, a non-receptor tyrosine kinase of the src family. 81, 62 AT 1 -receptor activation is also associated with phosphorylation and activation of the PDGFR. Unlike the EGFR, this process is not dependent on an increase in [Ca 2+ ] i and so does not appear to involve activation of CADTK. 82 Recent studies suggest that there may be two distinct mechanisms of activation of the PDGFR by the AT 1 -receptor; one secondary to action of c-src, the other a direct one involving production of ROS. It has also been proposed that the cellular localisation of the activated PDGFR may differ. 82
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Mitogen-activated kinases (ERK1/2)
Activation of mitogen-activated kinases such as ERK1/2 is a key event in growth factor signalling. The ERK1/2 pathway also appears to play an important role in mediating both protein synthesis 83 and DNA synthesis 84 in response to AT 1 -receptor activation. Although ras can be shown to be activated following AT 1 -receptor stimulation this may not be necessary for ERK1/2 activation. 48, 85 Surprisingly, there is evidence that activation of EDITORIAL REVIEW ERK1/2 may also contribute to AT 1 -induced contraction in some vessels. In rat and human resistance arteries [86] [87] [88] it was possible to inhibit contraction using the selective MEK antagonist PD98059. In contrast, in rat aorta PD98059 had no effect on Ang II-induced tone, although it was possible to demonstrate Ang II-induced phosphorylation of ERK1/2 in this artery. 68
Small G proteins (rho family)
Many vasoconstrictors, including Ang II, are linked to intracellular signalling systems by heterotrimeric G proteins. However, the possibility that monomeric GTP-ases (small G proteins) also have a role in smooth muscle function has received attention recently.The small G proteins that make up the rho family are a large family of ras-related proteins, which includes rho-A, rac-1 and cdc-42.
These GTP-ases are intimately involved in regulation of the actin cytoskeleton and play a wide range of roles in cell physiology. 89 Most recently, rhoA has been shown to be a major inhibitory regulator of myosin light chain phosphatase in smooth muscle. This action involves activation of rho kinase which can directly phosphorylate the regulatory subunit of myosin phosphatase. 45 A number of contractile agonists linked to heterotrimeric G proteins enhance the sensitivity of the contractile apparatus to changes in [Ca 2+ ] i by this mechanism, 45 but whether it contributes to contraction following AT 1 -receptor activation has not been examined. However, activation of rhoA has been implicated in Ang II-induced expression of c-fos and protein synthesis in cultured vascular smooth muscle cells. 90
Summary
Angiotensin II activates multiple signalling pathways in vascular smooth muscle. The precise pattern of signals and their relative importance to a particular functional response depends on both cell type and differentiation state. Although the contractile and trophic effects of Ang II are often thought of as distinct responses it is increasingly difficult to differentiate them in terms of signalling pathways. Since vasoconstriction and abnormal growth are both features of circulatory diseases such as hypertension and atherosclerosis a better understanding of the signalling pathways responsible for the vasoconstrictor and trophic actions of this peptide may help define novel therapeutic targets in cardiovascular disease.
